Setara Biosciences launched with $90 million in funding and a lead drug candidate in the clinic, targeting Charcot-Marie-Tooth disease type 2C and overactive bladder. The small-molecule program originated from Actio Biosciences, which was acquired by Jazz Pharmaceuticals, positioning Setara to continue development on a timetable aligned with early clinical advancement.